Cytokinetics, Incorporated (CYTK): Price and Financial Metrics


Cytokinetics, Incorporated (CYTK): $40.09

-0.59 (-1.45%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CYTK to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CYTK POWR Grades

  • Value is the dimension where CYTK ranks best; there it ranks ahead of 52.12% of US stocks.
  • The strongest trend for CYTK is in Momentum, which has been heading up over the past 178 days.
  • CYTK's current lowest rank is in the Sentiment metric (where it is better than 6.73% of US stocks).

CYTK Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for CYTK is -9.28 -- better than merely 1.88% of US stocks.
  • CYTK's price/sales ratio is 25.86; that's higher than the P/S ratio of 94.89% of US stocks.
  • Revenue growth over the past 12 months for CYTOKINETICS INC comes in at 587.85%, a number that bests 98.19% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to CYTK, based on their financial statements, market capitalization, and price volatility, are PRVB, MIRM, INSM, MRNS, and PXLW.
  • Visit CYTK's SEC page to see the company's official filings. To visit the company's web site, go to www.cytokinetics.com.

CYTK Valuation Summary

  • CYTK's price/sales ratio is 26; this is 441.67% higher than that of the median Healthcare stock.
  • CYTK's price/earnings ratio has moved down 0.8 over the prior 226 months.

Below are key valuation metrics over time for CYTK.

Stock Date P/S P/B P/E EV/EBIT
CYTK 2022-11-25 26.0 -240.9 -13.6 -16.9
CYTK 2022-11-23 25.9 -239.9 -13.6 -16.8
CYTK 2022-11-22 25.6 -237.2 -13.4 -16.7
CYTK 2022-11-21 25.5 -236.5 -13.4 -16.6
CYTK 2022-11-18 26.3 -243.7 -13.8 -17.0
CYTK 2022-11-17 25.7 -238.9 -13.5 -16.8

CYTK Growth Metrics

    Its 3 year cash and equivalents growth rate is now at 192.88%.
  • Its 2 year net cashflow from operations growth rate is now at -48.52%.
  • Its 3 year net cashflow from operations growth rate is now at -42.21%.
CYTK's revenue has moved up $130,586,000 over the prior 52 months.

The table below shows CYTK's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 148.231 -246.063 -282.145
2022-06-30 151.153 -200.793 -215.921
2022-03-31 65.028 -139.814 -257.655
2021-12-31 70.428 -142.522 -215.314
2021-09-30 21.55 -45.635 -228.674
2021-06-30 57.801 7.502 -155.763

CYTK's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CYTK has a Quality Grade of C, ranking ahead of 30.43% of graded US stocks.
  • CYTK's asset turnover comes in at 0.108 -- ranking 258th of 682 Pharmaceutical Products stocks.
  • VRTX, INBP, and MBIO are the stocks whose asset turnover ratios are most correlated with CYTK.

The table below shows CYTK's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.108 1 -0.236
2021-03-31 0.129 1 -0.244
2020-12-31 0.149 1 -0.286
2020-09-30 0.173 1 -0.292
2020-06-30 0.077 1 -0.445
2020-03-31 0.095 1 -0.461

CYTK Price Target

For more insight on analysts targets of CYTK, see our CYTK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $44.80 Average Broker Recommendation 1.5 (Moderate Buy)

CYTK Stock Price Chart Interactive Chart >

Price chart for CYTK

CYTK Price/Volume Stats

Current price $40.09 52-week high $55.80
Prev. close $40.68 52-week low $29.26
Day low $39.80 Volume 730,400
Day high $41.29 Avg. volume 1,151,180
50-day MA $44.96 Dividend yield N/A
200-day MA $42.78 Market Cap 3.79B

Cytokinetics, Incorporated (CYTK) Company Bio


Cytokinetics, Incorporated, a clinical stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The company was founded in 1997 and is based in South San Francisco, California.


CYTK Latest News Stream


Event/Time News Detail
Loading, please wait...

CYTK Latest Social Stream


Loading social stream, please wait...

View Full CYTK Social Stream

Latest CYTK News From Around the Web

Below are the latest news stories about CYTOKINETICS INC that investors may wish to consider to help them evaluate CYTK as an investment opportunity.

Cytokinetics (CYTK) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Salim Syed maintained a Buy rating on Cytokinetics (CYTK - Research Report) today and set a price target of $80.00. The company's shares closed yesterday at $40.33.Syed covers the Healthcare sector, focusing on stocks such as Cytokinetics, Biogen, and Coherus Biosciences. According to TipRanks, Syed has an average return of -17.4% and a 34.42% success rate on recommended stocks. Currently, the analyst consensus on Cytokinetics is a Strong Buy with an average price target of $75.40, which is an 86.96% upside from current levels. In a report released on November 9, H.C. Wainwright also reiterated a Buy rating on the stock with a $75.00 price target.

Carrie Williams on TipRanks | November 18, 2022

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Senti Biosciences (SNTI)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cytokinetics (CYTK – Research Report) and Senti Biosciences (SNTI – Research Report) with bullish sentiments. Cytokinetics (CYTK) In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Cytokinetics, with a price target of $80.00. The company's shares closed last Thursday at $39.12. According to TipRanks.

Brian Anderson on TipRanks | November 11, 2022

Cytokinetics Third Quarter 2022 Earnings: Misses Expectations

Cytokinetics ( NASDAQ:CYTK ) Third Quarter 2022 Results Key Financial Results Revenue: US$2.52m (down 54% from 3Q...

Yahoo | November 8, 2022

Cytokinetics Presents New Data at the American Heart Association Scientific Sessions 2022

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from two additional analyses from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), as well as an analysis of patients hospitalized for heart failure with reduced ejection fraction (HFrEF) from the Get With The Guidelines®-Heart Failure Registry, were presented at the American Heart Association Scienti

Yahoo | November 7, 2022

Cytokinetics (CYTK) Reports Q3 Loss, Tops Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of -7.56% and 11.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 3, 2022

Read More 'CYTK' Stories Here

CYTK Price Returns

1-mo -7.28%
3-mo -21.44%
6-mo -0.94%
1-year 2.72%
3-year 314.58%
5-year 410.70%
YTD -12.04%
2021 119.35%
2020 95.85%
2019 67.88%
2018 -22.45%
2017 -32.92%

Continue Researching CYTK

Want to see what other sources are saying about Cytokinetics Inc's financials and stock price? Try the links below:

Cytokinetics Inc (CYTK) Stock Price | Nasdaq
Cytokinetics Inc (CYTK) Stock Quote, History and News - Yahoo Finance
Cytokinetics Inc (CYTK) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.769 seconds.